FINWIRES · TerminalLIVE
FINWIRES

Hansoh Pharma's Application for Lung Cancer Drug Accepted in China

By

Hansoh Pharmaceutical's (HKG:3692) biologics license application for HS-20093 for injection was accepted by China's National Medical Products Administration.

The drug is for the treatment of adult patients with small cell lung cancer, according to a Wednesday Hong Kong bourse filing.

What else is happening in Asia?